Vaccine and Pharmaceutical Delivery Technologies

Primary container packaging

Desirable product attributes for low-resource settings

Many obstacles must be overcome before vaccines or essential medicines can be delivered to patients in developing countries. Upfront cost of goods, delays in transport, uneven temperatures, lack of adequate space in the cold chain, and unreliable electricity can compromise the delivery and performance of valuable health care commodities. Impractical product presentations and packaging can also exacerbate, rather than help to address, many of these challenges. To ensure coverage and health impact, PATH is working from a variety of angles to help manufacturers and technology developers understand, design, and achieve product attributes that help to protect from temperature extremes, ease cold chain impact, and improve efficiencies as well as effectiveness at point of use.

Maximizing efficiencies and product performance

Novel presentation and primary container packaging options that reduce product volume can ease storage and transport logistics, while fewer steps required for onsite product preparation can improve delivery efficiencies and correct use. Innovations in this technology space may also help to minimize the risks associated with contaminated medical waste. Highlights of our work include:

  • Single-dose presentations. A variety of prefilled single-dose plastic containers exist, including the Uniject™ injection system. There are several advantages to this presentation, including ease of use and compact non-glass packaging, which reduces product volume and facilitates safer disposal. Building from this foundation, PATH is exploring novel blow-fill-seal designs that may also enable single-dose formats to be physically conjoined into a multi-mono-dose strip, potentially increasing efficiencies across the entire value chain. Visit our page on single-dose presentations to learn more »
  • Multidose presentations. With the right packaging and delivery device, an appropriate multidose liquid stable formulation of rotavirus vaccine could reduce the manufacturing cost of the vaccine as well as its cold chain footprint. It could also simplify vaccination procedures in routine and campaign settings. In partnership with numerous technical collaborators, PATH is evaluating various formulation, packaging, and delivery technologies that together may help to create a new approach to introducing and administering multidose presentations of rotavirus vaccine in low-resource settings. Visit our page on multidose presentations to learn more »
  • Reconstitution technologies. Some vaccines and essential medicines require reconstitution, that is, the mixing of dry components with wet diluents, prior to use. This can cause challenges and lead to preparation errors, among other issues. Novel prefilled reconstitution technologies that keep a dried product and its diluent together during storage, transport, and delivery offer many advantages over current systems, including storage at the same temperature and a streamlined mixing process of the two parts. Visit our page on reconstitution technologies to learn more »

For information on how PATH is additionally working to ensure product appropriateness for low-resource settings, please visit the Presentation and Packaging page within our Vaccine and Pharmaceutical Supply Systems and Equipment portfolio site.